Drugs / BRIMAPITIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01570205 | Jul → Nov 2011 | — | Xigen SA | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02508337 | Jul 2015 → Jan 2016 | cataract | Xigen SA | Completed | No outcome recorded |
| Phase 3 | NCT02235272 | Sep 2014 → Dec 2015 | cataract | Xigen SA | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRIMAPITIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297650 ↗ |
| Known as | Brimapitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297650 ↗ |
| Known as | XG-102 | “The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain...” NCT02235272 ↗ |
| Action | Inhibit | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL4297650 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297650 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT01570205 ↗ |
| Target | MAPK10 | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL4297650 ↗ |